Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors
Conditions: Central Nervous System Tumor; Diffuse Intrinsic Pontine Glioma; Diffuse Midline Glioma; Ependymoma; Medulloblastoma, Childhood; Germ Cell Tumor; Atypical Teratoid/Rhabdoid Tumor; Primitive Neuroectodermal Tumor; Choroid Plexus Carcinoma; Pineoblastoma, Childhood; Glioma
Intervention: Biological: SCRI-CARB7H3(s); B7H3-specific chimeric antigen receptor (CAR) T cel
Sponsor: Seattle Children’s Hospital
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
December 5, 2019 /
/ in Oncology